White Papers

Home / Intelligence / White Papers


Gene Therapy Uptake: The Elephant in the Room

Gene therapies’ single administration nature presents a unique commercial challenge for biopharmaceutical companies; unlike traditional small molecule or biologic therapies that can be dosed chronically or repeatedly on an “as needed” basis, the one-time per patient administration of a gene therapy means that as time passes, the eligible population decreases in size. In this white paper, Trinity Life Sciences’ cell and gene therapy experts explore the unique opportunities that life sciences executives can utilize to unlock eligible patient populations and…

Read Now

Trinity Annual Drug Index

This report, the fifth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2019, scoring each on its commercial performance, therapeutic value, and R&D investment. 2019 saw 53 unique drug and biologic approvals, of which the majority were neurology (~23%) followed by oncology (~21%). In this…

Read Now

Global Market Access Trends: 2022 Edition

Trinity Life Sciences’ Evidence, Value, Access and Pricing experts identify the key global market access trends that will enable life sciences executives to identify opportunities, combat challenges and ultimately secure success in 2023.  Download this white paper to understand:  The five key market access trends emanating from 2022 that foretell the opportunities and challenges that lie ahead in 2023 (and beyond).  In-depth insights from 11 U.S. and 24 ex-U.S. payers from Trinity Life Sciences’ ‘Global Market Access Payer Survey’.  How…

Read Now

Cracking the Code of the Access Landscape in China

As the market becomes increasingly crowded and budget constraints continue in China, downward pricing pressure to secure National Reimbursement Drug List (NRDL) inclusion remains the top challenge for multinational pharma companies in this market. However, the significant uptake post-NRDL inclusion and broad access offer substantial opportunities for innovative products with clinical differentiation.   In this white paper, Trinity Life Sciences explores the highlights of the 2021 NRDL negotiation; including trends within the oncology, rare disease and chronic disease therapeutic areas…

Read Now

Reimbursement of Digital Therapeutics in the U.S.

Digital therapeutics (DTx) are impacting how patients are treated, interact with their providers and think about their own health. DTx have garnered interest from the investment community as well as pharma companies seeking an integrated digital offering. However, payers have not yet established a clear framework for integrating these technologies in their plans. Coverage of DTx to date has been limited and the outlook for it is unclear. We spoke to four medical and pharmacy directors from large payer organizations…

Read Now

Smarter Commercialization Investment for First Launch Biopharma

With more momentum than ever to bring innovative medicines to market, there is increased pressure on emerging companies to get the launch right. The industry has seen record-breaking funding for therapies in recent years, and many have been commercialized by emerging biopharma companies launching for the first time. For many of these emerging biopharma companies, optimizing commercial launch spend is a critical consideration pre- and post-launch, and with limited funds it can be easy to misjudge the timing of key…

Read Now

Valuing an Early-Stage Asset in Pharma and Biotech

In 2018, Trinity Life Sciences published a white paper titled, How to Approach Asset Valuation in Pharma & Biotech: Putting a price tag on emerging therapies. At the time, pharma and biotech firms were seeing venture investment growth of ~20% per year. This trend has only accelerated alongside the value of co-developments, partnerships, joint ventures, licensing agreements and other deals nearly doubling from 2019 to 2020. Quantifying the value of underlying assets throughout the clinical development process remains vital to…

Read Now

Empowering the Next-Generation Launch Model

The pharma industry has seen dramatic shifts in scientific innovation over the last decade with a trend toward orphan markets, personalized medicine, higher priced products and new modalities including cell and gene therapies, oligonucleotides and others. COVID served to further accelerate scientific innovation, driving a near record-breaking number of FDA approvals, astronomical venture capital funding and remarkably rapid development and rollout of ground-breaking products (including anti-virals, novel antibodies and mRNA vaccines). However, as Trinity Life Sciences discussed one year ago,…

Read Now

Reimagining Work Models in the Life Sciences: Implications for the Future of Work

The Changing Work Model for Life Sciences. When considering a work environment that will be sustainable in this new working world, life sciences companies have been examining policies and addressing how and where employees should work though lack objective sources of data to make informed decisions. The life sciences industry as a whole lacks work-model data. Like many organizations globally, certain work-model assumptions need to be validated or debunked. For example, Employees should be at company headquarters if or when…

Read Now

Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR

The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be…

Read Now